Scinai CEO discloses initial share holdings

Scinai Immunotherapeutics Ltd. director and Chief Executive Officer Amir Reichman filed an initial Form 3 showing his beneficial ownership in the company.

Rhea-AI Filing Summary

Scinai Immunotherapeutics Ltd. director and Chief Executive Officer Amir Reichman filed an initial Form 3 showing his beneficial ownership in the company. He reports direct holdings of 311,637,600 Ordinary Shares, which include restricted share units granted in January 2024 and December 2025 that vest over several years, subject to his continued service. He also holds 16,885 American Depositary Shares that are convertible at any time into 67,540,000 Ordinary Shares at no stated expiration date.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Reichman Amir

Role Chief Executive Officer

Type	Security	Shares	Price	Value
holding	American Depositary Shares	--	--	--
holding	Ordinary shares, no par value per share	--	--	--

Holdings After Transaction: American Depositary Shares — 67,540,000 contracts (Direct); Ordinary shares, no par value per share — 311,637,600 shares (Direct)

Footnotes (4)

1. F1. The Ordinary Shares are represented by American Depositary Shares, each of which currently represents four thousand Ordinary Shares.
2. F2. Includes 71,637,600 Ordinary Shares that are represented by restricted share units ("RSUs") that were granted on January 25, 2024, of which 25% vested on the six-month anniversary thereof, 8.33% vested on the 12-month anniversary thereof, and 66.66% vest in two equal annual installments thereafter, subject to the Reporting Person's continued service through such dates. Each RSU represents a contingent right to receive one Ordinary Share upon vesting.
3. F3. Includes 240,000,000 Ordinary Shares that are represented by RSUs that were granted on December 22, 2025, which vest in three equal annual installments thereafter, subject to the Reporting Person's continued service through such dates.
4. F4. Represents 16,885 American Depositary Shares, which are convertible at any time into 67,540,000 Ordinary Shares, at the holder's election and have no expiration date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Scinai Immunotherapeutics (SCNI) Form 3 filing show?

The Form 3 shows CEO Amir Reichman’s initial beneficial ownership in Scinai Immunotherapeutics. It details his direct Ordinary Share holdings, associated restricted share units, and American Depositary Shares that can be converted into Ordinary Shares at the holder’s election.

How many Ordinary Shares does Scinai CEO Amir Reichman report owning?

Amir Reichman reports direct ownership of 311,637,600 Ordinary Shares. This figure includes Ordinary Shares represented by restricted share units granted in January 2024 and December 2025, which vest over time subject to his continued service with the company.

What restricted share units (RSUs) are included in Amir Reichman’s Scinai holdings?

His holdings include 71,637,600 Ordinary Shares represented by RSUs granted on January 25, 2024 and 240,000,000 Ordinary Shares represented by RSUs granted on December 22, 2025. These RSUs vest in scheduled installments, contingent on his continued service.

How are Scinai Immunotherapeutics American Depositary Shares structured for the CEO?

The filing explains that each American Depositary Share currently represents four thousand Ordinary Shares. Reichman’s 16,885 American Depositary Shares are convertible at any time into 67,540,000 Ordinary Shares at his election and have no stated expiration date.

Does the Scinai Form 3 disclose recent insider buying or selling by the CEO?

The Form 3 functions as an initial statement of beneficial ownership and lists Amir Reichman’s existing holdings. It does not classify any of the reported positions as open-market purchases or sales, focusing instead on his current Ordinary Share, RSU, and ADS positions.

How do RSU vesting conditions affect Amir Reichman’s Scinai share ownership?

The RSUs convert into Ordinary Shares only as they vest over time. Vesting schedules for the January 2024 and December 2025 grants require Reichman’s continued service through specified anniversaries, meaning portions of the reported RSU-based Ordinary Shares are still contingent.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 09:53 AM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Reichman Amir

(Last) (First) (Middle)

C/O SCINAI IMMUNOTHERAPEUTICS LTD.

JERUSALEM BIOPARK, 2ND FLOOR

(Street)

JERUSALEM 9112002

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Scinai Immunotherapeutics Ltd. [ SCNI ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary shares, no par value per share(1)	311,637,600(2)(3)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
American Depositary Shares	(4)	(4)	Ordinary Shares	67,540,000	(4)	D

Explanation of Responses:

1. The Ordinary Shares are represented by American Depositary Shares, each of which currently represents four thousand Ordinary Shares.

2. Includes 71,637,600 Ordinary Shares that are represented by restricted share units ("RSUs") that were granted on January 25, 2024, of which 25% vested on the six-month anniversary thereof, 8.33% vested on the 12-month anniversary thereof, and 66.66% vest in two equal annual installments thereafter, subject to the Reporting Person's continued service through such dates. Each RSU represents a contingent right to receive one Ordinary Share upon vesting.

3. Includes 240,000,000 Ordinary Shares that are represented by RSUs that were granted on December 22, 2025, which vest in three equal annual installments thereafter, subject to the Reporting Person's continued service through such dates.

4. Represents 16,885 American Depositary Shares, which are convertible at any time into 67,540,000 Ordinary Shares, at the holder's election and have no expiration date.

Remarks:

Exhibit 24 - Power of Attorney.

	/s/ Amir Reichman	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)